`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`AKER BIOMARINE AS
`
`Petitioner
`
`
`
`v.
`
`
`
`NEPTUNE TECHNOLOGIES AND BIORESOURCES INC.
`
`Patent Owner
`
`
`
`CASE IPR: Unassigned
`
`Declaration of Dr. Richard B. van Breemen
`
`
`
`
`
`
`
`
`
`
`000001
`
`
`
`I, Richard B. van Breemen, Ph.D., hereby declare and say:
`
`
`
`1.
`
`I, Dr. Richard B. van Breemen, have been retained by counsel for
`
`Petitioner Aker BioMarine AS to provide an expert declaration in this action.
`
`2.
`
`I have reviewed U.S. Patent 8,278,351 (hereinafter ‘351 patent; Ex.
`
`1001) and the claims contained therein. It is my understanding that the ‘351 patent
`
`contains claims to krill extracts (claims 1-23); capsules, tablets, solutions, syrups
`
`or suspensions comprising the krill extracts (claims 24-46); foods, beverages or
`
`nutritional supplements comprising the krill extracts (claims 47-69); cosmetics
`
`comprising the krill extracts (claims 70-93); and Antarctic krill extracts (claim 94).
`
`3.
`
`As part of my engagement by the Respondents, I have been asked to
`
`provide analysis and opinions on the following:
`
`• whether certain krill extracts analyzed by Earl L. White on behalf
`
`of the Patentee contain the Claimed Phospholipids of the ‘351
`
`patent; and
`
`• whether any of the Claims of the ‘351 patent are invalid under 35
`
`U.S.C. § 102 as anticipated or under 35 U.S.C. § 103 as being
`
`rendered obvious.
`
`
`- 2 -
`
`000002
`
`
`
`
`
`4.
`
`I hold a B.A. degree in Chemistry from Oberlin College (1980) and a
`
`Ph.D. in Pharmacology from the Johns Hopkins University School of Medicine
`
`(1985).
`
`5.
`
`From 1986 to 1993, I was an Assistant Professor of Chemistry at
`
`North Carolina State University. During that time, I also served as Director of the
`
`Mass Spectrometry Laboratory for Biotechnology Research. In 1994, I joined the
`
`faculty of the University of Illinois at Chicago (UIC) as an Associate Professor of
`
`Medicinal Chemistry at the College of Pharmacy. In 2000, I was promoted to the
`
`position of Professor of Medicinal Chemistry and Pharmacognosy at the UIC
`
`College of Pharmacy, and I hold that position today.
`
`6.
`
`Since 1999, I have also worked at the UIC/NIH Center for Botanical
`
`Dietary Supplements Research (UIC Botanical Center). The UIC Botanical Center
`
`focuses on the study of the safety and efficacy of dietary supplements used by
`
`women. I was initially a Co-Director at the UIC Botanical Center when it was
`
`founded in 1999, and my primary responsibilities were supplement safety and all
`
`analytical aspects of supplements, including chemical standardization. Since 2011,
`
`I have been the Director of the UIC Botanical Center. In this role, I have been
`
`responsible for extraction and standardization of all botanical supplements for
`
`study. Since 1999, we have completed three Phase-1 trials and one Phase-2
`
`clinical trial at the UIC Botanical Center.
`
`
`- 3 -
`
`000003
`
`
`
`
`
`7.
`
`Since 2001, I have also held the administrative position of Assistant to
`
`the Director of the Research Resources Center at the University of Illinois at
`
`Chicago. In this position, I provide advice regarding campus needs in the area of
`
`mass spectrometry, and my laboratory serves as a central campus resource in mass
`
`spectrometry.
`
`8.
`
`Since 2010, I have been the leader of the Mass Spectrometry,
`
`Metabolomics and Proteomics Facility (MMPF) for the University of Illinois
`
`Cancer Center. MMPF provides analytical mass spectrometry support for cancer
`
`researchers for all branches of the University of Illinois. For examples, MMPF
`
`supports drug discovery, drug metabolism, pharmacokinetics, and clinical trials.
`
`9.
`
`I have done analytical work regarding materials of marine origin.
`
`Beginning in the 1990s, I performed research on carotenoids that included
`
`astaxanthin of marine origin utilizing tandem mass spectrometry (MS/MS). My
`
`publications stemming from that work include:
`
`• van Breemen RB, Schmitz HH, Schwartz SJ. Fast atom
`
`bombardment tandem mass spectrometry of carotenoids. J. Agric.
`
`Food Chem. 43, 384-389 (1995); and
`
`• van Breemen RB, Dong L, Pajkovic ND. Atmospheric pressure
`
`chemical ionization tandem mass spectrometry of carotenoids. Int.
`
`J. Mass Spectrom. 312, 163-172 (2012)
`
`- 4 -
`
`000004
`
`
`
`
`
`From 2006-2011, as a project leader on a program project grant entitled, “Natural
`
`inhibitors of carcinogenesis,” from the National Cancer Institute of the National
`
`Institutes of Health, I carried out drug discovery research utilizing mass
`
`spectrometry focused exclusively on natural products from marine sediment
`
`microorganisms. My publications stemming from that work include:
`
`• Choi Y, Jermihov K, Nam S-J, Sturdy M, Maloney K, Qiu X,
`
`Chadwick LR, Main M, Chen S-N, Mesecar AD, Farnsworth NR,
`
`Pauli GF, Fenical W, Pezzuto JM, van Breemen RB. Screening
`
`natural products for inhibitors of quinone reductase-2 using
`
`ultrafiltration LC-MS. Anal. Chem. 83, 1048-1052 (2011).
`
`PMC3034444; and
`
`• Kondratyuk TP, Park E-J, Yu R, van Breemen RB, Asolkar RN,
`
`Murphy BT, Fenical W, Pezzuto JM. Novel marine phenazines as
`
`potential cancer chemopreventive and inflammatory agents. Mar.
`
`Drugs, 10, 451-464 (2012). PMC3297008
`
`I have also done work in the field of lipid chemistry. For example, between 1990-
`
`1995, I carried out early mass spectrometry-based structural studies of
`
`phosphatidylinositols (PI) including:
`
`
`- 5 -
`
`000005
`
`
`
`
`
`• van Breemen RB, Wheeler JJ, Boss WF. Identification of carrot
`
`inositol phospholipids by
`
`fast atom bombardment mass
`
`spectrometry. Lipids, 25, 328-334 (1990); and
`
`• van Breemen, RB. Structural analysis of phosphatidylinositol from
`
`carrot cell membranes by fast atom bombardment and tandem
`
`mass spectrometry. In Mass Spectrometry in the Molecular
`
`Sciences: A Tutorial, pp. 443-451, ed. by Gross ML. Kluwer
`
`Academic Publishers, Dordrecht, 1992. (Invited Contribution)
`
`I also published numerous papers regarding the structural characterization and
`
`identification of
`
`lipophilic carotenoids using high performance
`
`liquid
`
`chromatography-mass spectrometry (LC-MS) and LC-MS/MS, including:
`
`• van Breemen RB, Schmitz HH, Schwartz SJ. Continuous-flow fast
`
`atom bombardment liquid chromatography/mass spectrometry of
`
`carotenoids. Anal. Chem. 65, 965-969 (1993);
`
`• van Breemen RB. Electrospray
`
`liquid chromatography-mass
`
`spectrometry of carotenoids. Anal. Chem. 67, 2004-2009 (1995);
`
`
`- 6 -
`
`000006
`
`
`
`
`
`• van Breemen RB. Innovations in carotenoid analysis using liquid
`
`chromatography/mass spectrometry. Anal. Chem. 68, 299A-304A
`
`(1996);
`
`• van Breemen RB, Huang C-H, Tan Y, Sander LC, Schilling AB.
`
`Liquid chromatography/mass spectrometry of carotenoids using
`
`atmospheric pressure chemical ionization. J. Mass Spectrom. 31,
`
`975-981 (1996); and
`
`• van Breemen RB. Liquid chromatography/mass spectrometry of
`
`carotenoids. Pure Appl. Chem. 69, 2061-2066 (1997).
`
`10. Since 1986, I have been teaching analytical chemistry and mass
`
`spectrometry at the university level, including at the graduate level. In the Fall of
`
`1986, I created and taught a course at North Carolina State University entitled,
`
`CH527 Mass Spectrometry, which I taught until 1992. In that course I instructed
`
`students regarding the theory and application of mass spectrometry. From 1987-
`
`1993, I also taught a course called CH525 Physical Methods in Organic Chemistry.
`
`In that course I instructed students regarding the structure determination of organic
`
`compounds using a variety of spectroscopy data. Since joining the faculty at UIC
`
`in 1994, I have taught a course called MDCH 562 Spectroscopy in Medicinal
`
`Chemistry. In that course I instruct graduate students regarding the interpretation
`
`- 7 -
`
`000007
`
`
`
`
`
`of mass spectra and the structure determination of drugs and natural products using
`
`a combination of analytical techniques including nuclear magnetic resonance,
`
`infrared spectroscopy, ultraviolet spectroscopy, and mass spectrometry. More than
`
`45 graduate students and 19 post-doctoral fellows have graduated from my
`
`laboratory, all with advanced training in mass spectrometry.
`
`11.
`
`I have authored or co-authored more than 250 articles in peer-
`
`reviewed journals and have co-authored more than a dozen book chapters,
`
`including chapters for texts related to mass spectrometry, food analytical
`
`chemistry, and lipid analysis. I am the American Regional Editor of the scientific
`
`journal Biomedical Chromatography and am also on the editorial board of Assay
`
`and Drug Development Technologies, and I serve as an ad hoc reviewer for
`
`approximately 40 scientific journals, reviewing approximately 35 papers each year
`
`on average.
`
`12. On more than 30 occasions, I have served as an advisor to Federal
`
`Government Public Advisory Committees at the National Institutes of Health
`
`(NIH) on topics ranging from cancer, complementary and alternative medicine,
`
`small business proposals related to biomedical research (SBIR), and shared
`
`instrument proposals, including those related to mass spectrometry.
`
`13. My research is interdisciplinary and currently focuses on safety and
`
`efficacy of botanical dietary supplements and cancer chemoprevention. My
`
`
`- 8 -
`
`000008
`
`
`
`
`
`laboratory at UIC routinely prepares samples for analysis using LC-MS, including
`
`specialized biomedical applications of LC-MS. On a daily basis we use high
`
`performance liquid chromatography (HPLC) and ultrahigh pressure liquid
`
`chromagraphy (UHPLC). On a daily basis, we also extract specimens of
`
`botanicals as well as human and animal specimens, including serum, tissue, and
`
`urine, in preparation for analysis.
`
`14. A more detailed account of my education, work experience,
`
`publications, honors, memberships in professional societies, selected speaking
`
`engagements, a listing of my previous and present graduate students and
`
`postdoctoral research associates, and other qualifications—as well as a list of cases
`
`during the last four years in which I have signed a Protective Order, have testified
`
`as an expert either at a trial, hearing, or deposition, or have submitted statements /
`
`opinions—is listed in my Curriculum Vitae attached as Attachment A to this
`
`Declaration.
`
`15.
`
`I am being compensated at my customary consulting rate of $300 per
`
`hour for my time spent on this matter. I am also being reimbursed for reasonable
`
`expenses incurred with respect to this matter, and my university is being paid a rate
`
`of $162 per hour for access to its LC/MS facilities. My compensation is not
`
`contingent on the conclusions I reach in my expert report or the outcome of this
`
`litigation.
`
`
`- 9 -
`
`000009
`
`
`
`
`
`16.
`
`I have reviewed and considered, in the preparation of this report, the
`
`documents in the below table.
`
`Exhibit
`
`Description
`
`No.
`
`1001
`
`U.S. Pat. No. 8,278,351 to Sampalis (“’351”)
`
`1005
`
`Certified translation of Ex. 1072: Fisheries Agency, General Report
`
`on Research and Development of Techniques in Processing and
`
`Utilization of Marine Products, Chapter 6, Development of
`
`technology for recovery of valuable substances (astaxanthin) from
`
`krill, by Takao Fujita, pp. 273-307 (March 1985) (“Fujita”) ;
`
`Certificate of Translation provided as Ex. 1073.
`
`1008
`
`Canadian Patent No. 1098900, titled Method for the Processing of
`
`Krill to Produce Protein, Lipids and Chitin (“Rogozhin”)
`
`1031
`
`Winther et al., Elucidation of Phosphatidylcholine Composition in
`
`Krill Oil Extracted from Euphausia superba, Lipids 46(1):25-36
`
`(2011)(“Winther”)
`
`1043
`
`Expert Witness Report of Dr. Theodore Welch submitted in relation
`
`
`- 10 -
`
`0000010
`
`
`
`
`
`to ITC Investigation No. 337-TA-877 (“Welch”)
`
`1051
`
`Declaration of Dr. Earl White submitted during prosecution of parent
`
`patent U.S. 8,030,348 (“2011 White Decl.”)
`
`1054
`
`Declaration of Dr. Yeboah submitted during inter partes
`
`reexamination of parent patent U.S. 8,030,348 (“Yeboah Reexam
`
`Decl.”)
`
`1055
`
`Supplemental Declaration of Dr. Earl White submitted during inter
`
`partes reexamination of parent patent U.S. 8,030,348 (“White Supp.
`
`Reexam. Decl.”)
`
`1056
`
`Declaration of Dr. Shahidi submitted during inter partes
`
`reexamination of parent patent U.S. 8,030,348 (Shahidi Reexam.
`
`Decl.”
`
`1057
`
`Declaration of Dr. Tina Sampalis submitted during inter partes
`
`reexamination of parent patent U.S. 8,030,348 (Sampalis”)
`
`1061
`
`April 2, 2012 Response to Office Action, ‘351 patent
`
`1062
`
`Provisional Application No. 60/307,842 (Priority document for the
`
`
`- 11 -
`
`0000011
`
`
`
`
`
`‘351 patent)
`
`1066
`
`Declaration of Dr. van Breemen submitted during Ex parte
`
`Reexamination of the ‘351 patent (Van Breemen ‘351 Reexam.
`
`Decl.”
`
`1067
`
`Declaration of Dr. van Breemen submitted during Ex parte
`
`Reexamination of the ‘348 patent (van Breemen ‘348 Reexam Decl.”
`
`1069
`
`U.S. Patent No. 8,030,348
`
`
`
`17. Additionally,
`
`I
`
`submitted declarartions during
`
`reexamination
`
`proceedings concerning the ‘351 Patent and during reexamination proceedings
`
`concerning U.S. Patent No. 8,030,348 (the ‘348 patent; Ex. 1069), to which the
`
`‘351 patent claims priority (Declaration of Dr. van Breemen submitted during Ex
`
`parte Reexamination of the ‘351 patent; Ex. 1066; (Declaration of Dr. van
`
`Breemen submitted during Inter partes Reexamination of the ‘348 patent; Ex.
`
`1067). The data and analysis in those declarations are incorporated at ¶¶ 90-101
`
`below.
`
`18. The ‘351 patent discusses certain phospholipid molecules, including
`
`phosphatidylcholine
`
`(abbreviated
`
`as
`
`“PC”),
`
`phosphatidylethanolamine
`
`
`- 12 -
`
`0000012
`
`
`
`
`
`(abbreviated as “PE”), and phosphaditlinositol
`
`(abbreviated as “PI”).
`
`Phospholipids PC, PE and PI are naturally occurring biochemicals consisting of a
`
`glycerol molecule to which is attached a polar group at one end, a fatty acid acyl
`
`group in the middle (called the sn-2 position) and another fatty acid acyl group at
`
`the other end (called the sn-1 position). The polar group consists of a phosphate
`
`group to which is attached a choline, ethanolamine or an inositol group.
`
`19. Various analytical chemistry techniques are referred to in this report
`
`and in the case materials I have considered for purposes of my analysis. These
`
`analytical chemistry techniques including TLC, HPLC, UHPLC, GC, and LC/MS.
`
`20. TLC. Thin Layer Chromatography is a technique used to separate
`
`compounds in a mixture. Generally, a compound mixture is applied to a plate or
`
`sheet that is coated with an adsorbent material. A solvent is then applied to the
`
`plate. As the solvent travels up the plate (through capillary action), the different
`
`compounds in the mixture will travel with it while adsorbing to and desorbing from
`
`the stationary coat on the plate at different rates, achieving separation. TLC may be
`
`used preparatively to separate mixtures of compounds or it may be used
`
`qualitatively to characterize a mixture. Although co-chromatography of two
`
`compounds during TLC does not provide sufficient chemical information for
`
`compound identification, TLC can show that two compounds are not identical.
`
`
`- 13 -
`
`0000013
`
`
`
`
`
`21. HPLC and UHPLC. High performance liquid chromatography
`
`(HPLC) and ultrahigh pressure liquid chromatography (UHPLC) are techniques
`
`used to separate compounds in mixtures while in solution. Separations occur on a
`
`stationary phase (usually silica or chemically derivatized silica) that is packed into
`
`a column. Solvent (called the mobile phase) is pumped through the column up at
`
`pressures typically up to 6,000 psi (HPLC) or 19,000 psi (UHPLC), and a
`
`compound mixture is injected into the flowing of solvent and onto the column. Due
`
`to differences in interactions between the stationary phase and the compounds in
`
`the mixture such as adsorption, the compound mixture can be separated as it flows
`
`through the column such that each compound elutes (is washed out or removed) at
`
`a different time. UHPLC typically provides better chromatographic separations and
`
`faster separations than can HPLC.
`
`22. GC. Gas chromatography is a technique used to separate compounds
`
`in mixtures while in the gas phase. Separations occur in a column containing a
`
`stationary phase that is either packed into the column or on the inner wall of the
`
`column. The compound mixture is injected into a moving stream of gas (usually
`
`helium or hydrogen) that carries the compounds into the column. Compounds
`
`separate as they partition differently between the stationary phase and the carrier
`
`gas and then elute from the column at different times.
`
`
`- 14 -
`
`0000014
`
`
`
`
`
`23. LC-MS
`
`and LC-MS/MS.
`
` Liquid
`
`chromatography-mass
`
`spectrometry and LC-tandem mass spectrometry involve the interfacing of HPLC
`
`or UHPLC to a mass spectrometer and a tandem mass spectrometer, respectively.
`
`Mass spectrometers convert molecules to gas phase ions that are then separated
`
`and weighed in an electromagnetic field according to their mass-to-charge
`
`properties. High resolution mass spectrometers can weigh ions with such accuracy
`
`that the elemental compositions of the ions can be determined. For the
`
`measurement of the Claimed Phospholipids in my laboratory, I used a hybrid ion
`
`trap time-of-flight (IT-TOF) high resolution mass spectrometer and a triple
`
`quadrupole tandem mass spectrometer. Tandem mass spectrometers provide a
`
`second dimension of ion characterization by selecting a specific precursor ion,
`
`fragmenting it (usually using a gas-phase process called collision-induced
`
`dissociation) and then recording all or specific fragment ions that provide structural
`
`information about the precursor ion.
`
`24. The ‘351 patent is titled “Natural Marine Source Phospholipids
`
`Comprising Polyunsaturated Fatty Acids and Their Applications.” The ‘351 patent
`
`lists one inventor, Fotini Sampalis. I understand that the ‘351 patent is assigned to
`
`Neptune Technologies & Bioressources, Inc.
`
`25.
`
`It is my understanding that the ‘351 patent contains claims to krill
`
`extracts (claims 1-23); capsules, tablets, solutions, syrups or suspensions
`
`
`- 15 -
`
`0000015
`
`
`
`
`
`comprising the krill extracts (claims 24-46); foods, beverages or nutritional
`
`supplements comprising the krill extracts (claims 47-69); cosmetics comprising the
`
`krill extracts (claims 70-93); and Antarctic krill extracts (claim 94). I understand
`
`that claims 1, 24, 47, 70 and 94 of the ’351 Patent are independent claims and that
`
`claims 2-23 depend on claim 1, claims 25-46 depend on claim 24, claims 48-69
`
`depend on claim 47, and claims 71-93 depend on claim 70.
`
`26. The common feature of the independent claims (claims 1, 24, 47, 70
`
`and 94) is the
`
`requirement of a phospholipid of the general formula (I),
`
`
`
`wherein R1 and R2, each together with the respective
`
`carboxyl groups
`
`to which each
`
`is attached, each
`
`independently represent a docosahexaenoic acid (DHA)
`
`or an eicosapentaenoic acid (EPA) residue, and X is —
`
`CH2CH2NH3, —CH2CH2N(CH3)3, or
`
`
`- 16 -
`
`0000016
`
`
`
`
`
`.
`
`The dependent claims add limitations on other components of the
`
`composition such as omega-3 content, polyunsaturated fatty acid content, content
`
`of other lipid classes, metal content and antioxidant content.
`
`27. Because a phospholipid of general formula I is in each independent
`
`claim, it is also required in each of the dependent claims.
`
`28. General formula I comprises the following twelve phospholipids:
`
`Phospholipid Class
`
`R1 and R2
`
`—CH2CH2NH3
`
`(Phosphatidylethanolamine or “PE”)
`
`R1: DHA
`
`R2: EPA
`
`R1: EPA
`
`R2: DHA
`
`R1: EPA
`
`R2: EPA
`
`R1: DHA
`
`R2: DHA
`
`
`- 17 -
`
`0000017
`
`
`
`—CH2CH2N(CH3)3
`
`(Phosphatidylcholine or “PC”)
`
`
`
`(Phosphatidylinositol or “PI”)
`
`
`
`R1: DHA
`
`R2: EPA
`
`R1: EPA
`
`R2: DHA
`
`R1: EPA
`
`R2: EPA
`
`R1: DHA
`
`R2: DHA
`
`R1: DHA
`
`R2: EPA
`
`R1: EPA
`
`R2: DHA
`
`R1: EPA
`
`R2: EPA
`
`R1: DHA
`
`R2: DHA
`
`Throughout my report, I will refer to these twelve phospholipids as the “Claimed
`
`Phospholipids.”
`
`
`- 18 -
`
`0000018
`
`
`
`
`
`29. Claim 1 of the ‘351 Patent states: “[a] krill extract comprising: a
`
`phospholipid of the general formula (I),
`
`
`
`wherein R1 and R2, each together with the respective
`
`carboxyl groups
`
`to which each
`
`is attached, each
`
`independently represent a docosahexaenoic acid (DHA)
`
`or an eicosapentaenoic acid (EPA) residue, and X is —
`
`CH2CH2NH3, —CH2CH2N(CH3)3, or
`
`
`
`and wherein
`
`the extract
`
`is suitable
`
`for human
`
`consumption.
`
`30. Claim 24 of the ‘351 Patent is identical to claim 1, except that claim
`
`24 additionally states “[a] capsule, tablet, solution, syrup, or suspension
`
`comprising a krill extract …”
`
`
`- 19 -
`
`0000019
`
`
`
`
`
`31. Claim 47 of the ‘351 Patent is identical to claim 1, except that claim
`
`47 additionally states “[a] food, beverage, energy bar or nutritional supplement…”
`
`32. Claim 70 of the ‘351 Patent is identical to claim 1, except that claim
`
`70 additionally states “[a] cosmetic preparation…”
`
`33. The claims of the ‘351 Patent that depend on claim 1 (claims 2-23),
`
`the claims that depend on claim 24 (claims 25-46), the claims that depend on claim
`
`47 (claims 48-69), and the claims that depend on claim 70 (claims 72-93) (with the
`
`exception of claim 71) mirror each other in the following manner:
`
`Claims
`
`
`
`2, 25,
`
`The extract according to claim [1, 24, 47, 70] wherein the extract has a
`
`48, 72
`
`total phospholipid concentration in an amount of about 40% w/w,
`
`wherein about represents ±10%.
`
`3, 26,
`
`The extract according to claim [1, 24, 47, 70], wherein the extract has a
`
`49, 73
`
`total phospholipid concentration in an amount of about 45% w/w,
`
`wherein about represents ±20%.
`
`
`- 20 -
`
`0000020
`
`
`
`
`
`Claims
`
`
`
`4, 27,
`
`The extract according to claim [1, 24, 47, 70], further comprising an
`
`50, 74
`
`additional lipid, wherein the additional lipid is selected from the group
`
`consisting of monoglycerides, triglycerides, cholesterols, mixtures
`
`thereof, and free fatty acids.
`
`5, 28,
`
`The extract according to claim [1, 24, 47, 70], wherein the extract has a
`
`51, 75
`
`concentration of free fatty acids of about 5% w/w of the lipids in the
`
`extract.
`
`6, 29,
`
`The extract according to claim [1, 24, 47, 70], wherein the extract further
`
`52, 76
`
`comprises polyunsaturated fatty acids which comprise at least 15% w/w
`
`of the lipids in the extract.
`
`7, 30,
`
`The extract according to claim [1, 24, 47, 70], wherein the extract further
`
`53, 77
`
`comprises polyunsaturated fatty acids which comprise at least 40% w/w
`
`of the lipids in the extract.
`
`8, 31,
`
`The extract according to claim [1, 24, 47, 70], wherein the extract further
`
`54, 78
`
`comprises polyunsaturated fatty acids which comprise at least 45% w/w
`
`of the lipids in the extract.
`
`
`- 21 -
`
`0000021
`
`
`
`
`
`Claims
`
`
`
`9, 32,
`
`The extract according to claims [6, 29, 52, 76], [7, 30, 53, 77], or [8, 31,
`
`55, 79
`
`54, 78], wherein the polyunsaturated fatty acids are omega-3 fatty acids.
`
`10, 33,
`
`The extract according to claim [1, 24, 47, 70], wherein DHA and EPA
`
`56, 80
`
`comprise at least 32% w/w of the lipids in the extract.
`
`11, 34,
`
`The extract according to claim [1, 24, 47, 70], wherein DHA and EPA
`
`57, 81
`
`comprise at least 35% w/w of the lipids in the extract.
`
`12, 35,
`
`The extract according to claim [1, 24, 47, 70], further comprising a metal.
`
`58, 82
`
`13, 36,
`
`The extract according to claim [12, 35, 58, 82], wherein the metal is zinc,
`
`59, 83
`
`selenium or a mixture thereof.
`
`14, 37,
`
`The extract according to claim [13, 36, 59, 83], wherein the zinc
`
`60, 84
`
`comprises at least 0.005 mg/100 g of the extract and the selenium
`
`comprises less than 3 mg/100 g of the extract.
`
`15, 38,
`
`The extract according to claim [4, 27, 50, 74], wherein the fatty acid
`
`61, 85
`
`composition of the lipids in the extract is about:
`
`
`- 22 -
`
`0000022
`
`
`
`
`
`Claims
`
`
`
`16, 39,
`
`The extract according to claim [15, 38, 61, 85], wherein the total fatty
`
`62, 86
`
`acid composition of all the lipids in the extract is:
`
`17, 40,
`
`The extract according to claim [16, 39, 62, 86], wherein the total fatty
`
`63, 87
`
`acid composition of all the lipids is:
`
`18, 41,
`
`The extract according to claim [4, 27, 50, 74], comprising:
`
`64, 88
`
`19, 42,
`
`The extract of claim [1, 24, 47, 70], wherein one of R1 and R2 is EPA
`
`65, 89
`
`and the other is DHA.
`
`20, 43,
`
`The extract of claim [1, 24, 47, 70], wherein R1 and R2 is EPA.
`
`66, 90
`
`21, 44,
`
`The extract of claim [1, 24, 47, 70], wherein R1 and R2 is DHA.
`
`67, 91
`
`22, 45,
`
`The extract of claim [1, 24, 47, 70], further comprising an antioxidant.
`
`68, 92
`
`
`- 23 -
`
`0000023
`
`
`
`
`
`Claims
`
`
`
`23, 46,
`
`The extract of claim [22, 45, 68, 92], wherein the antioxidant is selected
`
`69, 93
`
`from the group consisting of vitamin A, vitamin E, carotenoid, beta-
`
`carotene, astaxanthin, canthaxanthin, flavonoids, and mixtures thereof.
`
`34. Claim 71 depends on indepdent Claim 70, and recites: “The cosmetic
`
`preparation of claim 70, wherein the topical cosmetic product is one or more of a
`
`moisturizing cream and a sun-block product.”
`
`35. Claim 94 of the ’351 Patent recites:
`
`An Antarctic krill oil extract comprising: a phospholipid
`
`of the general formula (I),
`
`
`
`wherein R1 and R2, each together with the respective
`
`carboxyl groups
`
`to which each
`
`is attached, each
`
`independently represent a docosahexaenoic acid (DHA)
`
`
`- 24 -
`
`0000024
`
`
`
`
`
`or an eicosapentaenoic acid (EPA) residue, and X is —
`
`CH2CH2NH3, —CH2CH2N(CH3)3, or
`
`
`
`the extract is extracted under conditions suitable for
`
`preserving an effective amount of a phospholipid having
`
`two independently selected fatty acid chains within the
`
`same [molecule/phospholipid] selected from EPA and
`
`DHA;
`
`the extract comprises phospholipids in an amount of at
`
`least 40% w/w;
`
`the extract comprises omega-3 fatty acids in an amount
`
`of at least 15% w/w;
`
`the extract comprises astaxanthin and
`
`the extract is suitable for human consumption.
`
`
`
`
`- 25 -
`
`0000025
`
`
`
`
`
`36. The Fisheries Agency, General Report on Research and Development
`
`of Techniques in Processing and Utilization of Marine Products (March 1985) (the
`
`“General Report”) is a publication compiling studies relating to marine products.
`
`Section II of the General Report is focused on the development of krill as a food
`
`product. It contains a Chapter 6 (pp. 273-307) written by Takao Fujita and entitled
`
`“Development of utilization technology of a valuable resource (astaxanthin) in
`
`krill” (the “Fujita Reference”; Ex. 1005).
`
`37. The General Report including the Fujita Reference was published at
`
`least in 1986, fifteen years before the earliest claimed priority date of the Asserted
`
`Patents, and is therefore prior art to all Asserted Claims of the Asserted Patents
`
`under at least 35 U.S.C. § 102(b).
`
`38.
`
`I have reviewed the Expert Witness Report of Theodore F. Welch,
`
`Ph.D Regarding Public Accessibility of Certain References (Welch Expert
`
`Witness Report; Ex. 1043), and I understand that the Fujita Reference has been
`
`publicly accessible at the Ministry of Agriculture, Forestry and Fisheries Library
`
`(“MAFF Library”) in Tokyo, Japan since at least as early as November 1986, at
`
`least because the General Report including the Fujita Reference was indexed,
`
`catalogued, shelved, and publicly searchable by author and title by this date, and
`
`was fully cataloged and searchable by subject heading within a reasonable amount
`
`of time thereafter.
`
`
`- 26 -
`
`0000026
`
`
`
`
`
`39. On Monday, August 19, 2013, I also spoke with Ms. Endou, Ms.
`
`Sugiyama and Mr. Yoshihama (librarians at MAFF), who separately confirmed the
`
`following information for me:
`
`• The General Report including the Fujita Reference is in the MAFF
`
`Library’s collection and has been since at least as early as November
`
`1986;
`
`• The MAFF Library record for the General Report indicates its
`
`accession date at the MAFF Library was November 1986;
`
`
`
`• A stamp appearing on the first page of the table of contents for the
`
`General Report also indicates that its accession date at the MAFF
`
`Library was November 1986;
`
`
`
`• MAFF Library records, including the record for the General Report,
`
`have been electronically searchable since April 2001 by at least
`
`author, keyword, and/or title fields, and searchable by card catalog
`
`since the accession date of the General Report; and
`
`
`
`• The MAFF Library is generally open to the public on weekdays.
`
`
`- 27 -
`
`0000027
`
`
`
`
`
`
`
`40. The General Report discusses research directed toward use of krill for
`
`food products. For example, the Fujita Reference states:
`
`
`
`(Fujita (Ex. 1005) at page 275) Thus, the Fujita Reference discusses methods for
`
`extracting “valuable” components from krill for use in human food products with
`
`the objective that the resulting extracts comply with safety restrictions and
`
`“promot[e] effective utilization of krill.” (Id.)
`
`
`- 28 -
`
`0000028
`
`
`
`
`
`41. Multiple solvent extraction methods are
`
`taught in the Fujita
`
`Reference. The Fujita Reference teaches that among the solvents tested, hexane
`
`was chosen for further study because it was considered safe and appropriate for use
`
`in foods:
`
`In contrast, while the extractability with hexane was somewhat worse,
`
`this solvent is widely utilized in the extraction of vegetable oil, and it
`
`is believed to be the most practical solvent from the standpoint of
`
`safety, price and solvent recovery, etc. Therefore a study was
`
`performed to look at improving the extractability of lipids and
`
`carotenoids through adjustment of the water content.
`
`
`
`(Id., pages 283-284.)
`
`
`
`42. The Fujita Reference teaches at least three different extraction
`
`methods using hexane: (a) extraction with hexane with adjusted water content
`
`(Id., pages 284-285 (extraction test a with hexane with adjusted water content));
`
`(b) extraction with a hexane-ethanol mixture (Id. (extraction test b with
`
`hexane/ethanol)); and (c) a “once-through” extraction with hexane (Id., page 285
`
`(extraction test c)). I tested each of the forgoing three hexane extraction methods
`
`
`- 29 -
`
`0000029
`
`
`
`
`
`to determine if they inherently result in the Claimed Phospholipid. A detailed
`
`description of my processes for creating these krill extracts is set out below.
`
`43. The extraction with hexane with adjusted water content is reported in
`
`the Fujita Reference as follows:
`
`
`
`(Id., p. 285) The Fujita Reference reports results obtained “when performing
`
`extraction with reflux and heating for 1 hour using each of these solvents at an
`
`amount that was five times greater than that of the krill meal.” (Id., pages 282)
`
`44. Accordingly, to test this process, the following steps were performed:
`
`i.
`
`Krill meal used for this experiment was supplied by Aker. The
`
`meal arrived frozen on dry ice and was stored in a 4°C
`
`refrigerator upon receipt until use.
`
`ii.
`
`750 mL of hexane, water corresponding to a meal water content
`
`of 20%, and 150 gram of the krill meal were added to a 2 Liter
`
`round bottom flask. (The moisture content of the meal was
`
`
`- 30 -
`
`0000030
`
`
`
`
`
`4.3%. Accordingly, approximately 24 mL of water was added
`
`to achieve a 20% water content)
`
`iii. A magnetic stir bar was added to the round bottom flask and set
`
`to stir at 50 rpm. Extraction was performed with reflux and
`
`heating for 1 hour at 59°C while stirring the material.
`
`iv.
`
`The material was filtered under reduced pressure using a filter.
`
`v.
`
`The filtration residue was washed three times using 750 mL of
`
`hexane.
`
`vi.
`
`The procedures ii. through v. were repeated to ensure sufficient
`
`oil for analysis.
`
`vii. The filtrate and wash solution from both extractions were
`
`combined in a round bottom flask and the majority of the
`
`hexane was distilled off at 200 Torr and 30°C.
`
`viii. Solvent removal was completed by distillation at 40 Torr and
`
`70°C in order to obtain the oil.
`
`
`- 31 -
`
`0000031
`
`
`
`
`
`Reduced pressures of 40 Torr and 200 Torr, respectively, were obtained using a
`
`vacuum pump equipped with a pressure gauge and bleed valve, and temperatures
`
`of 70°C and 30°C were obtained using a water bath equipped with a thermometer.
`
`45. The Fujita Reference also teaches that hexane/ethanol at a ratio of
`
`79:21 can be substituted for hexane/water. (Id., pp. 284-285.) For example, the
`
`Fujita Reference states:
`
`Next, an intermediate extractor was used to perform manufacturing
`
`tests with three types of so